Indefinite Delivery Contract 75N95024D00020

Award Date 6/20/24
Last Date to Order 6/19/30
Contracting Federal Agency
National Institute on Drug Abuse
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Service Contract Act
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The federal contract IDV award is for safety evaluation and toxicology studies and related services to support drug development efforts of the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). The prime contractor, SRI International, a nonprofit research and development institute, will provide in vitro and in vivo exploratory and Investigational New Drug (IND)-directed toxicology studies for small molecule and biologic...
This indefinite delivery contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The $48.6 million multiple-award IDC has a 6-year ordering period from June 2024 to June 2030. The contract aims to procure safety evaluation and toxicology studies and related services to support drug development efforts at NCATS....
The National Institutes of Health National Institute of Neurological Disorders and Stroke awarded an indefinite delivery/indefinite quantity contract to IIT Research Institute of Chicago, Illinois with a potential value of $174,470,000. The contract aims to procure pharmacology and toxicology services to support the Pharmacology and Toxicology for Therapeutics Program. Services include non-GLP ADME/PK/TOX studies for up to 10 projects annually, GLP enabling toxicology studies for up to 5...
The key products and services being delivered under this federal contract IDV award from the National Cancer Institute (NCI) are preclinical toxicology studies on small molecule drug candidates for cancer and other indications. The prime contractor, IIT Research Institute (IITRI), a division of the Illinois Institute of Technology, will conduct non-GLP and GLP toxicology assessments in mice and dogs to support Investigational New Drug (IND) applications. IITRI holds several significant IDIQ...
The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, has awarded a $48.6 million multiple-award indefinite delivery contract to conduct safety evaluation and toxicology studies in support of drug development. The contract has a 6-year ordering period and allows NCATS to issue task orders for in vitro and in vivo safety testing services, including genetic toxicology, general toxicology, and pharmacology...
This Indefinite Delivery Contract (IDC) was awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The contract, with a ceiling value of $0, is part of the Preclinical Agent Development Assays 2012-2016 program and supports preclinical in vitro and in vivo agent development assays. Under this IDC, IITRI provides a range of preclinical research...
This federal indefinite delivery contract was awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the non-profit IIT Research Institute (IITRI). The $19 million PREVENT Toxicology and Pharmacology Testing (PREVENT TOX) IDIQ contract vehicle enables NCI to efficiently access IITRI's preclinical research capabilities on an as-needed basis to support the development of cancer prevention therapies. Task orders issued under this...
The National Center for Advancing Translational Sciences (NCATS), a civilian agency, has awarded an indefinite delivery contract (IDC) worth up to $48,622,546 to Charles River Laboratories, Inc. to provide safety evaluation and toxicology studies and related services to support drug development. The contract has a period of performance from August 2024 to August 2030. Under this IDC, Charles River will perform in vitro and in vivo exploratory and Investigational New Drug (IND)-directed...
This indefinite delivery contract (IDC) was awarded by a U.S. federal government agency to IIT Research Institute (IITRI), a non-profit contract research organization. The IDC is a multiple-award vehicle with a $0 ceiling value and an ultimate completion date of September 30, 2007. Under this IDC, IITRI provides a range of preclinical research services to support federal agencies such as the National Institutes of Health (NIH), including the National Cancer Institute (NCI), National Institute of...
This Indefinite Delivery Contract is a parent IDIQ vehicle awarded by the National Institutes of Health's National Institute of Neurological Disorders and Stroke to Southern Research Institute, a non-profit research organization. The Pharmacology and Toxicology for Therapeutics Program (PTTP) IDIQ has a total potential value of $174,470,000 and a period of performance through September 12, 2026. Under this IDIQ, Southern Research has been awarded multiple task orders to provide drug discovery,...
  • 75N95024D00020
    Indefinite Delivery Contract
  • 1
    Federal Contract Awards

This is a multiple award indefinite delivery contract awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to conduct safety evaluation and toxicology studies to support drug development. The $48.6 million contract has a 6-year ordering period from June 2024 to June 2030.

The contractor, IIT Research Institute (IITRI), a non-profit research organization, will perform in vitro and in vivo exploratory and IND-directed toxicology studies for small molecule and biologic drug candidates to support regulatory filings with the FDA, such as IND, NDA, and BLA applications. This includes activities like mitochondrial toxicity assays, in vivo dosing studies, and reproductive toxicology evaluations. IITRI has extensive experience conducting preclinical drug development services for federal agencies across multiple therapeutic areas. The contract is awarded under full and open competition without set-asides.

Generated 9/13/24, 9:08 AM